Date: 2014-09-02
Type of information: Collaboration agreement
Compound: Chiesi Ventures
Company: Chiesi Farmaceutici (Italy) A. M. Pappas & Associates (USA - NC)
Therapeutic area: Rare diseases
Type agreement:
Action mechanism:
Disease:
Details: * On September 2, 2014, the Chiesi Group announced the launch of its venture capital fund, Chiesi Ventures, via a strategic collaboration with A. M. Pappas & Associates. Chiesi Ventures will complement the strategic interest of the Chiesi Group in the area of rare diseases by investing in early stage opportunities and expanding the Chiesi network in the US among universities, venture capital investors, rare disease patient organizations and entrepreneurial companies developing treatments for rare diseases. Chiesi Ventures will have offices in Boston, MA, Research Triangle Park, NC and Parma, Italy and will focus on investment opportunities in the US and Europe. It will operate as an independent investment vehicle while maintaining a strategic connection with the Chiesi Group. Chiesi Ventures will leverage A. M. Pappas & Associates’ expertise and network to access and assess deals and opportunities, lead investments and manage transactions. A. M. Pappas & Associates is dedicated to the development of life science companies, products, technologies, and other entrepreneurial opportunities. Through its Pappas Ventures business unit, A. M. Pappas & Associates has worked with such companies as Plexxikon (acquired by Daiichi Sankyo), Ultragenyx Pharmaceutical (IPO), Lumena Pharmaceuticals (acquired by Shire), LEAD Therapeutics (acquired by BioMarin Pharmaceutical), and Balance Therapeutics.
Financial terms:
Latest news:
